active screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening
active screening of adverse effects of anticancer therapy based on specific questionnaire + quality of life screening: Based on the Questionnaire for the Assessment of Difficulties after the completion of cancer treatment, the attending physician will assess the need for intervention and respond appropriately to the reported problems. Intervention is assessed as education by the physician, the use of medication, or referral of the patient to a specialized outpatient clinic.
Study summary
The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* The patient understands the information provided and agrees to participate in the study.
* Age 18 years or older.
* Histologically confirmed invasive breast cancer or invasive prostate cancer.
* Completion of the acute phase of curative oncological therapy:
* for breast cancer: curative surgery performed + completed neoadjuvant/adjuvant chemotherapy and completed adjuvant radiotherapy, if indicated
* for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy
* The patient is available for follow-up within 12 months of enrollment in the study.
Exclusion Criteria:
* Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4/6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)
* Neoadjuvant/adjuvant therapy did not include chemotherapy (breast cancer).
* Recurrence of cancer
* Metastatic disease
* History of other primary malignancy (except for non-melanoma skin cancer)
Primary outcome measure(s)
Impact of active monitoring of adverse effects on quality of life — Upon enrollment (baseline), six and twelve months after baseline Compare the quality of life of breast and prostate cancer survivors between the interventional group, in which adverse effects are actively monitored using the Questionnaire for the Assessment of Difficulties after Cancer Treatment, and the control group.
Trial sites (1)
Facility
City
Region
Status
Masaryk Memorial Cancer Institute
Brno
Czechia
Recruiting
More Masaryk Memorial Cancer Institute trials in Czechia
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
